Latest filing published 04 Jun 2026 for Biomarin Pharmaceutical INC. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Filings by Barbara W. Bodem span 5 companies, the busiest being Enovis Corp, Hill-Rom Holdings, Inc. and Biomarin Pharmaceutical Inc. We count 22 filings; the first trade dates from 1 November 2021 and the latest from 2 June 2026.
Not one of the filings records a straightforward purchase or sale on the market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Most recently, on 4 June 2026, the filings show a share grant in Biomarin Pharmaceutical Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
22 of 22 declarations